High-Dose Enalapril Treatment Reverses Myocardial Fibrosis in Experimental Uremic Cardiomyopathy
2011

High-Dose Enalapril Treatment Reverses Myocardial Fibrosis in Experimental Uremic Cardiomyopathy

Sample size: 73 publication Evidence: moderate

Author Information

Author(s): Tyralla Karin, Adamczak Marcin, Benz Kerstin, Campean Valentina, Gross Marie-Luise, Hilgers Karl F., Ritz Eberhard, Amann Kerstin

Primary Institution: Department of Pathology, University of Erlangen-Nürnberg, Erlangen, Germany

Hypothesis

Can high-dose enalapril treatment reverse existing cardiovascular alterations in rats with renal failure?

Conclusion

High-dose ACE-I treatment causes partial, but not complete, reversal of cardiovascular changes in subtotally nephrectomized rats.

Supporting Evidence

  • Enalapril treatment significantly improved myocardial fibrosis in SNX animals.
  • Left ventricular weight was significantly lower in SNX+E compared to untreated SNX.
  • Alternative antihypertensive treatment showed no effect on myocardial fibrosis.

Takeaway

This study found that giving a strong heart medicine called enalapril to sick rats helped improve their heart problems, but it didn't fix everything.

Methodology

Male Sprague Dawley rats underwent subtotal nephrectomy or sham operation, followed by treatment with enalapril or other antihypertensive drugs, and evaluation of heart and aorta.

Potential Biases

Potential bias in treatment allocation and measurement due to the nature of animal studies.

Limitations

The study was conducted on rats, which may not fully represent human conditions.

Participant Demographics

Male Sprague Dawley rats, mean body weight 379±27 g.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0015287

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication